Media headlines about TESARO (NASDAQ:TSRO) have been trending positive recently, according to AlphaOne. The research group, a service of Accern, identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. TESARO earned a news impact score of 0.39 on AlphaOne’s scale. AlphaOne also assigned media coverage about the biopharmaceutical company an impact score of 94 out of 100, indicating that recent news coverage is extremely likely to have an effect on the stock’s share price in the near term.
Here are some of the media stories that may have impacted AlphaOne’s rankings:
- TESARO, Inc. (TSRO) Rating Reiterated by Cowen and Company (americanbankingnews.com)
- Tesaro Comes Roaring Back From Much Lower Open (feeds.benzinga.com)
- TESARO, Inc. (TSRO) Receives Consensus Rating of “Buy” from Brokerages (americanbankingnews.com)
- Venbio Select Advisor Decreased Tesaro (TSRO) Position by $6.16 Million; Shares Declined; Hayek Kallen Investment … – BZ Weekly (bzweekly.com)
- ETFs with exposure to TESARO, Inc. : June 15, 2017 (finance.yahoo.com)
TESARO (NASDAQ TSRO) traded down 0.94% during mid-day trading on Monday, hitting $142.96. The stock had a trading volume of 4,019,036 shares. TESARO has a one year low of $36.71 and a one year high of $192.94. The firm’s 50-day moving average price is $145.90 and its 200 day moving average price is $151.16. The company’s market cap is $7.70 billion.
TESARO (NASDAQ:TSRO) last posted its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($2.55) EPS for the quarter, missing the consensus estimate of ($2.26) by $0.29. The business had revenue of $3.10 million during the quarter, compared to analyst estimates of $3.84 million. TESARO had a negative net margin of 910.35% and a negative return on equity of 96.49%. The firm’s quarterly revenue was up 909.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($2.22) earnings per share. On average, equities research analysts anticipate that TESARO will post ($8.74) EPS for the current year.
Several analysts recently commented on TSRO shares. Zacks Investment Research downgraded shares of TESARO from a “hold” rating to a “sell” rating in a research report on Wednesday, March 22nd. Piper Jaffray Companies assumed coverage on shares of TESARO in a research note on Wednesday, April 12th. They set an “overweight” rating and a $180.00 target price on the stock. Leerink Swann reiterated a “market perform” rating on shares of TESARO in a research note on Monday, March 20th. Robert W. Baird lowered shares of TESARO from an “outperform” rating to a “neutral” rating and increased their target price for the stock from $127.00 to $182.00 in a report on Monday, February 27th. Finally, Jefferies Group LLC increased their target price on shares of TESARO from $80.00 to $124.00 and gave the stock a “hold” rating in a report on Monday, March 27th. Nine equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $173.27.
In other news, VP Edward C. English sold 8,500 shares of the business’s stock in a transaction on Tuesday, June 6th. The stock was sold at an average price of $138.65, for a total value of $1,178,525.00. Following the completion of the transaction, the vice president now directly owns 5,396 shares of the company’s stock, valued at $748,155.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Martin H. Jr. Huber sold 829 shares of the business’s stock in a transaction on Monday, April 3rd. The stock was sold at an average price of $153.02, for a total value of $126,853.58. Following the completion of the transaction, the senior vice president now directly owns 6,522 shares of the company’s stock, valued at $997,996.44. The disclosure for this sale can be found here. Insiders own 34.60% of the company’s stock.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with our FREE daily email newsletter.